- Conditions
- Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy from Age-related Macular Degeneration, X-lined Retinoschisis, Retinal Dystrophies
- Interventions
- Not listed
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Irvine, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome
- Interventions
- Not listed
- Lead sponsor
- Foundation Fighting Blindness
- Other
- Eligibility
- Not listed
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2037
- U.S. locations
- 1
- States / cities
- Columbia, Maryland
- Conditions
- X-linked Retinoschisis
- Interventions
- ATSN-201
- Biological
- Lead sponsor
- Atsena Therapeutics Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 14 more
- Conditions
- Retinoschisis, X-Linked
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Retinoschisis
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 9 Months to 100 Years
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Rochester, Michigan
- Conditions
- Retinoschisis, X-Linked
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Retinitis Pigmentosa, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy From Age-related Macular Degeneration, X-linked Retinoschisis, Retinal Dystrophies
- Interventions
- Not listed
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- X-linked Retinoschisis, XLRS
- Interventions
- Dorzolamide 2% TID or brinzolamide 1% TID
- Drug
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 7 Years and older · Male only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas
- Conditions
- X-linked Retinoschisis
- Interventions
- rAAV2tYF-CB-hRS1
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 6 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 9
- States / cities
- San Francisco, California • Miami, Florida • Baltimore, Maryland + 6 more
- Conditions
- Retinoschisis, X-Linked
- Interventions
- RS1 AAV Vector
- Biological
- Lead sponsor
- VegaVect, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Retinal Detachment, Proliferative Vitreoretinopathy, Retinoschisis
- Interventions
- Triamcinolone, Bupivicaine Hydrochloride
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia